Journal of Cancer Research and Clinical Oncology

, Volume 130, Issue 4, pp 222–224

Tyrosine kinase receptor expression in thymomas

  • John D. Henley
  • Oscar W. Cummings
  • Patrick J. Loehrer, Sr.
Original Paper



Promising new therapies for neoplasia include tyrosine kinase receptor antagonists. Tyrosine kinase oncogenes present an appealing anti-tumor drug target since they play an integral role in a variety of cellular responses including cell proliferation and differentiation. We previously demonstrated a high rate of epidermal growth factor receptor (EGFR) expression in advanced-stage thymic epithelial tumors. More recently, we have examined c-KIT (CD117) expression in a similar series of tumors.


Tumor from 35 patients seen at our institution for treatment of advanced-stage thymoma was available. Twenty thymomas and 15 thymic carcinomas were assessed for c-KIT expression. Tissue sections of tumor were stained immunohistochemically with anti-c-KIT (Oncogene). Either cytoplasmic or membrane staining was considered positive. Appropriate controls were performed. Positive staining for c-KIT was present in 12 tumors (11 thymic carcinomas and 1 thymoma).


In distinction to EGFR, c-KIT is expressed more commonly in thymic carcinomas (73% of carcinomas) than in thymoma (5% of thymomas).


An EGFR negative/c-KIT positive staining pattern is typical of thymic carcinoma, whereas thymomas are generally EGFR positive/c-KIT negative. Possible therapeutic implications of these observations remain to be determined.


c-KIT CD 117 Tyrosine kinase Thymoma Thymic carcinoma 

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • John D. Henley
    • 1
  • Oscar W. Cummings
    • 1
  • Patrick J. Loehrer, Sr.
    • 2
  1. 1.Department of PathologyIndiana University School of Medicine, Clarian Health PartnersIndianapolisUSA
  2. 2.Department of MedicineIndiana University School of MedicineIndianapolisUSA

Personalised recommendations